Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Receivables: 2019-2025

Historic Receivables for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $100.7 million.

  • Harmony Biosciences Holdings' Receivables rose 23.50% to $100.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $382.6 million, marking a year-over-year increase of 20.13%. This contributed to the annual value of $83.0 million for FY2024, which is 11.99% up from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' Receivables is $100.7 million, which was up 8.25% from $93.0 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Receivables peaked at $106.0 million during Q1 2025, and registered a low of $23.6 million during Q1 2021.
  • Over the past 3 years, Harmony Biosciences Holdings' median Receivables value was $81.5 million (recorded in 2024), while the average stood at $80.4 million.
  • Data for Harmony Biosciences Holdings' Receivables shows a peak YoY skyrocketed of 103.39% (in 2021) over the last 5 years.
  • Harmony Biosciences Holdings' Receivables (Quarterly) stood at $34.8 million in 2021, then surged by 57.10% to $54.7 million in 2022, then spiked by 35.44% to $74.1 million in 2023, then rose by 11.99% to $83.0 million in 2024, then rose by 23.50% to $100.7 million in 2025.
  • Its Receivables stands at $100.7 million for Q3 2025, versus $93.0 million for Q2 2025 and $106.0 million for Q1 2025.